secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0001213900-23-076241
Event type: debt
Sentiment:  negative
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma obtains waiver from Lind Global on market cap default condition through Feb 2024
--------------------------------------------------------------------------------

- Lind Global waives any Event of Default for market cap below $12.5M for 10 consecutive days through Feb 23, 2024.
- Lind retains conversion rights under Note sections 2.2(a) and 2.2(c)(2)(x), which could result in stock issued at significant discount.
- Outstanding principal of Note is $2,754,167; Mandatory Default Amount set at 115% = $3,167,292.05.
- If market cap does not increase or further waiver/amendment not obtained, an event of default could materially affect liquidity and operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023076241/0001213900-23-076241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023076241/ea185104-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-076241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer